Moleculin CEO Highlights Progress in Pivotal MIRACLE Study for AML Treatment — Moleculin Biotech, Inc.

Event summary

Moleculin released a CEO Corner segment on March 11, 2026, discussing the MIRACLE Study evaluating Annamycin in combination with cytarabine for relapsed or refractory AML.
The adaptive Phase 3 trial includes an initial cohort of 45 patients, with interim unblinding planned to assess safety and efficacy.
Treatment completion for the first 45 patients is expected in the near term, progressing as planned across clinical sites.
The study builds on earlier MB-106 Study results, where AnnAraC demonstrated overall survival outcomes exceeding historical benchmarks.

The big picture

Moleculin's MIRACLE Study represents a critical milestone in the development of Annamycin for relapsed or refractory AML, a challenging patient population. The adaptive trial design, informed by FDA input, aims to streamline the regulatory pathway. Success in this study could position Annamycin as a differentiated therapy in the AML treatment landscape, addressing both efficacy and cardiotoxicity concerns associated with current anthracyclines.

What we're watching

Regulatory Pathway: How the interim unblinding results will influence the FDA's feedback and the most efficient regulatory path forward.
Clinical Execution: The pace at which Moleculin can complete treatment for the initial 45 patients and advance the MIRACLE Study.
Financing Needs: Whether Moleculin can secure the significant additional financing required to conduct its clinical trials as planned.